Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (272)	4/22/2003 8:08:47 PM
From: Torben Noerup Nielsen	Respond to of 4232

Peter, The main problem with the Salk vaccine is that it doesn't lead to production of mucosal antibodies. And since the transmission of polio is via the intestines, that means that you can be vaccinated with the Salk vaccine and still act as a host for polio. It simply won't go to the CNS which means that the risk of paralytic polio is gone. But the Salk vaccine doesn't eradicate the virus. The Sabin vaccine is taken orally and gives rise to antibodies in the intestines where polio enters. Thus it not only prevents paralytic polio; it also stops the virus from being transmitted. A good way of stopping polio is initial vaccination with the Salk vaccine followed by vaccination using the Sabin vaccine. This reduces the risk associated with reversal inherent in the Sabin vaccine. A general problem with killed vaccines is that they produce mainly humoral immunity and no cell mediated immunity. Torben